scholarly article | Q13442814 |
meta-analysis | Q815382 |
P6179 | Dimensions Publication ID | 1091840059 |
P356 | DOI | 10.1186/S12920-017-0291-0 |
P8608 | Fatcat ID | release_3pc63flr2zfsxftemnjoyilguq |
P932 | PMC publication ID | 5606117 |
P698 | PubMed publication ID | 28927418 |
P50 | author | Ritushree Kukreti | Q87148604 |
P2093 | author name string | Puneet Talwar | |
Suman S Kushwaha | |||
Shrikant Kukreti | |||
Chitra Rawat | |||
Debleena Guin | |||
Manish Kumar Mishra | |||
P2860 | cites work | Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease | Q64763354 |
Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects | Q64939817 | ||
G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease | Q67211130 | ||
Research diagnostic criteria for Parkinson's disease | Q68601645 | ||
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease | Q79464324 | ||
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease | Q79759867 | ||
Etiology and pathogenesis of Parkinson's disease | Q84231134 | ||
Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease | Q87536077 | ||
Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease | Q21144949 | ||
Parkinson's disease: clinical features and diagnosis | Q22242021 | ||
Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's disease | Q24289214 | ||
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease | Q24596763 | ||
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies | Q24606055 | ||
Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease | Q28205539 | ||
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease | Q28244731 | ||
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. | Q28262863 | ||
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD | Q28375036 | ||
Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism | Q28579756 | ||
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease | Q28943440 | ||
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. | Q29417095 | ||
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
STRING v10: protein-protein interaction networks, integrated over the tree of life | Q29615545 | ||
Identification of a novel Parkinson's disease locus via stratified genome-wide association study | Q30571934 | ||
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study | Q31932059 | ||
Role of the ubiquitin proteasome system in Parkinson's disease | Q33307874 | ||
Systematic reviews of genetic association studies. Human Genome Epidemiology Network | Q33414801 | ||
Parkinson's Disease Society Brain Bank, London: overview and research | Q33463550 | ||
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes | Q33991709 | ||
PharmGKB: the Pharmacogenetics Knowledge Base | Q34010656 | ||
Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease | Q34326909 | ||
Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease | Q34399250 | ||
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats | Q34417485 | ||
Diagnostic criteria for Parkinson disease | Q34489839 | ||
Levodopa and the progression of Parkinson's disease | Q34553278 | ||
Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane | Q35197211 | ||
Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease | Q35821201 | ||
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors | Q35953962 | ||
??? | Q64763388 | ||
??? | Q64764709 | ||
??? | Q64797105 | ||
The genetics of Parkinson's disease: progress and therapeutic implications | Q36626825 | ||
ARF6 and GASP-1 are post-endocytic sorting proteins selectively involved in the intracellular trafficking of dopamine D₂ receptors mediated by GRK and PKC in transfected cells | Q36681759 | ||
The role of common genetic risk variants in Parkinson disease | Q36941992 | ||
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013 | Q36954017 | ||
Variation in dopamine genes influences responsivity of the human reward system | Q37062116 | ||
STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement | Q37314650 | ||
Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions. | Q37583417 | ||
Clinical and pathological features of Parkinson's disease | Q38213626 | ||
Parkinson's disease pharmacogenomics: new findings and perspectives. | Q38241678 | ||
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations | Q38510678 | ||
Essential myoclonus and myoclonic dystonia | Q41018229 | ||
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease | Q41168222 | ||
Editorial: Parkinson's disease: cell vulnerability and disease progression | Q41846573 | ||
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia | Q42072420 | ||
Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. | Q42708909 | ||
The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia | Q42792207 | ||
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa | Q43243392 | ||
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients | Q43270106 | ||
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients | Q43592846 | ||
Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity | Q44221551 | ||
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism | Q44471611 | ||
Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. | Q44687266 | ||
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation | Q44782063 | ||
Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study. | Q45007058 | ||
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease | Q45301027 | ||
Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. | Q45345781 | ||
Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. | Q46003760 | ||
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism | Q46057259 | ||
Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms | Q46205987 | ||
Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease | Q46407825 | ||
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study | Q46433089 | ||
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease | Q46555889 | ||
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. | Q46910776 | ||
A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway | Q48518599 | ||
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. | Q48852969 | ||
Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease | Q48880365 | ||
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. | Q50547059 | ||
Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. | Q51172907 | ||
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. | Q51418735 | ||
Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. | Q53008274 | ||
Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. | Q53287838 | ||
Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. | Q54313392 | ||
Study Quality Assessment in Systematic Reviews of Research on Intervention Effects | Q57970160 | ||
Genetic basis for individual variations in pain perception and the development of a chronic pain condition | Q60628070 | ||
Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients? | Q61648204 | ||
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients | Q61648243 | ||
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease | Q62588922 | ||
P433 | issue | 1 | |
P921 | main subject | levodopa | Q300989 |
P304 | page(s) | 56 | |
P577 | publication date | 2017-09-19 | |
P1433 | published in | BMC Medical Genomics | Q15754662 |
P1476 | title | A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease | |
P478 | volume | 10 |